Tr1X has received an $8 million grant from the California Institute for Regenerative Medicine to support its Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for preventing graft-versus-host disease in mismatched stem cell transplants.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.